CITIC Capital, CDH investments and Legend Capital have invested $300 million in SF Freight, a sub-brand of Chinese courier company SF Express, through a convertible note issue.
SpaceX-inspired global fervor about the possibilities of space technology has infiltrated China. Some start-ups appear well set for commercial lift-off, but many others will misfire
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
Community group buying businesses are beginning to struggle in China despite considerable VC investment. Fresh produce retailer Benlai believes its online-to-offline hybrid model is more sustainable
Chinese online real estate marketplace Fangdd Network raised $78 million in its US IPO, having reduced the size of the offering, and traded flat on its first day on NASDAQ.
I-Mab Biopharma, the product of a CBC Group-engineered merger of two Chinese drug developers, has announced plans for a NASDAQ IPO.
Fangdd Network, a Chinese online real estate marketplace backed by the likes of FountainVest Partners and CDH Investments, has filed to list in the US.
Chinese online fresh produce retailer Benlai Group has raised $200 million in the first tranche of a Series D round led by Mingde Holding. Existing investors Gaorong Capital and CDH investments re-upped.
Belle International – the Chinese footwear retailer privatized by Hillhouse Capital and CDH Investments just over two years ago – is spinning out its sports retail unit through an IPO.
CDH Investments has participated in the $120 million second tranche of a Series D round for TuSimple, a China and US-based developer of autonomous driving technology for trucks.
CDH Investments’ wealth management platform, which sources investment opportunities for the firm’s network of high net worth clients, is raising a $200 million emerging markets fund that will primarily target India.
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, saw its stock drop almost 20% on debut following a HK$1.23 billion ($157 million) IPO in Hong Kong.
Yunji, a Chinese membership-based e-commerce platform, gained 29% on its NASDAQ trading debut following a $121 million IPO that was largely covered by two of its private equity investors.
Concerns around valuations, commercialization timelines, deal targeting, and brand perceptions are coming into focus as China’s AI ecosystem catapults to global prominence
IDG Capital Partners and CDH Investments have led an RMB300 million ($45 million) Series B round for China-based Creative Biosciences, a manufacturer of testing kits for colon cancer.
Yunji, a Chinese membership-based e-commerce platform that typically works with small-scale retailers that don’t have the resources to compete online, has filed to list in the US.
Private equity investors believe it will become easier to take companies public in China as the country steps up the pace of capital markets reform, creating a system that is more in line with international norms.
Private equity firms that held back from investing in 2018 as uncertainty gripped China’s economy now see reasons to get busy again. With few macro tailwinds, GPs will be judged on their ability to pick winners
CDH Investments is seeking approximately $1 billion for its second China growth fund, just over two years after raising $800 million for the debut vehicle.
Medbanks raises a $59 million Series C round to update the traditional information networks that make China’s growing oncology industry tick. Quality of management has proven a critical investment factor
Beijing and Shanghai-based Medbanks, an information service provider specializing in cancer care, has raised RMB400 million ($59 million) in Series C funding led by CLP Fund.
Chinese commercial rocket developer iSpace has completed an extended Series A round of undisclosed size led by CDH Investments, with participation from Matrix Partners China and local VC Dianke Xinghe.
As Asian GPs trial a range of operational value-add strategies with an eye on shifting market dynamics, they are discovering that helping portfolio companies requires self-inspection